Metabolic Syndrome News and Research

Latest Metabolic Syndrome News and Research

Genetic expression can be modified with natural substances to prevent chronic illness

Research findings demonstrating how genetic expression can be modified with natural substances to prevent chronic illness was the topic of an address by Jeffrey Bland, Ph.D., FACN, FACB, at the 8th Annual Scripps Center for Integrative Medicine 2011 conference in San Diego, California, January 13 - 16.

20 Jan 2011

Breastfeeding can partially offset long-term side effects of cancer treatment

Women who have survived childhood cancer should be advised to breastfeed if they can, in order to offset some of the negative health effects of their earlier cancer treatment. According to Susan Ogg and colleagues from St. Jude Children's Research Hospital in Memphis, Tennessee, making women aware of the benefits of breastfeeding should be part of routine post-cancer diet and healthy lifestyle recommendations.

20 Jan 2011

Scripps Research receives NIH grant to develop therapies for circadian rhythm disorders

The Scripps Research Institute has been awarded $3.17 million over four years to develop compounds that will counteract disruptions of the human biological clock - the circadian rhythm that regulates our patterns of activity and rest over a 24-hour daily cycle.

19 Jan 2011

First Round Table Meeting on Metabolomics & Diabetes takes place in Vienna

Metabolomic biomarker research is a young research area that carries great hopes for both medicine and the nutritional sciences, particularly for the early detection of genetically determined diseases.

14 Jan 2011

Shionogi brings KAPVAY ADHD drug to the U.S market

Shionogi Inc., the U.S.-based group company of Shionogi & Co., Ltd., today announced a true milestone as it marks the first commercial availability for the non-central nervous system stimulant medication KAPVAY™, an extended-release oral formulation of clonidine for Attention Deficit Hyperactivity Disorder (ADHD) in children and adolescents.

10 Jan 2011

Esperion Therapeutics commences ETC-1002 Phase 2 clinical study for cardio-metabolic diseases

Esperion Therapeutics, a privately held biotechnology company working to discover, develop and commercialize treatments for cardiovascular and metabolic diseases, today announced that it has initiated a Phase 2 clinical study for ETC-1002, the company's lead product candidate.

7 Jan 2011

Liver transplant recipients develop PTMS, face high risk of cardiovascular disease

Researchers from Israel have determined that more than half of liver transplant recipients develop post-transplantation metabolic syndrome, placing them at greater risk for cardiovascular disease.

7 Jan 2011

Diet low in micronutrients can contribute to metabolic syndrome

Results of an epidemiological study conducted by researchers at the Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University and the Corporacion Ecuatoriana de Biotecnologia showed that the metabolic syndrome, a condition that increases a person's risk of developing cardiovascular disease and type 2 diabetes, was prevalent in a low-income urban community in Ecuador and that a poor diet low in micronutrients appeared to contribute.

5 Jan 2011

Florida Hospital, Sanford-Burnham and Takeda enter obesity research collaboration

Florida Hospital, Sanford-Burnham Medical Research Institute (Sanford-Burnham), and Takeda Pharmaceutical Company Limited (Takeda)(TSE: 4502), announced today that they have signed a research agreement to form a collaboration to discover and evaluate new therapeutic approaches to obesity, a growing worldwide health problem. The partnership aligns complementary strengths in biomedical research, clinical research and drug development to identify and validate obesity- related biomarkers and new peripheral molecular targets of mutual interest.

29 Dec 2010

Pregnant women veterans face increase risk of mental health problems

Pregnancy among women veterans who served in Iraq and Afghanistan appears to increase their risk for mental health problems such as depression, anxiety, and post-traumatic stress disorder, according to a study published in Journal of Women's Health, a peer-reviewed journal published by Mary Ann Liebert, Inc. The paper is available free online.

22 Dec 2010

Isis commences ISIS-APOCIIIRx Phase 1 trial in hypertriglyceridemia

Isis Pharmaceuticals, Inc. announced the initiation of a Phase 1 study of ISIS-APOCIIIRx, an antisense drug designed to lower triglycerides to treat a variety of diseases associated with elevated triglycerides. Hypertriglyceridemia, a condition characterized by elevated levels of triglycerides, is an independent risk factor for cardiovascular disease and is a component of numerous cardiovascular and metabolic diseases, including metabolic syndrome.

21 Dec 2010

VIVUS seeks marketing approval of QNEXA in the EU

VIVUS, Inc. today announced that the company filed a Marketing Authorization Application (MAA) with the European Medicines Agency (EMA) for QNEXA® (phentermine/topiramate) Controlled Release Capsules in the European Union (EU). The proposed indication in the EU is for the treatment of obesity, including weight loss and maintenance of weight loss, and should be used in conjunction with a mildly hypocaloric diet.

20 Dec 2010

Study links large waistline to increased risk of heart problems and type 2 diabetes

Researchers at Eastern Virginia Medical School’s Strelitz Diabetes Center and the school’s department of physiological sciences have published research showing a strong link between a large waistline and increased risk of Type 2 diabetes and cardiovascular disease.

14 Dec 2010

VIVUS submits briefing document to FDA in effort to secure regulatory approval for QNEXA

VIVUS, Inc. today announced that the company, as part of its continuing effort to secure regulatory approval for QNEXA® in the U.S., submitted a briefing document to the Food and Drug Administration (FDA) designed to address items in the FDA's Complete Response Letter (CRL), issued on October 28, 2010. The company also announced that the Endocrine and Metabolic Division of the FDA has granted VIVUS a meeting in the second half of January 2011 to discuss the content of the proposed resubmission.

14 Dec 2010

Spherix Phase 2 diabetes clinical trial determines minimum D-tagatose dose capable of reducing HbA1c

Spherix Incorporated, an innovator in biotechnology for therapy in diabetes, metabolic syndrome and atherosclerosis; and providers of technical and regulatory consulting services to food, supplement, biotechnology and pharmaceutical companies, today announced that its Phase 2 diabetes clinical trial, designed to determine the minimum dose of D-tagatose capable of reducing HbA1c, found that the minimum dose capable of affecting HbA1c (7.5 g three-times daily, or TID) was within the range of doses tested

10 Dec 2010

Expert panel explores how to engage pediatricians, primary care physicians in preventing childhood obesity

As the prevalence of childhood obesity approaches epidemic levels, physicians on the "front line" need to become more involved in obesity prevention and weight management to reverse this dangerous trend among their young patients. But several obstacles discourage pediatricians and other primary care physicians from taking a more active role in managing childhood obesity.

9 Dec 2010

Exposure to polluted air leads to accumulation of abdominal fat and insulin resistance

Exposure to polluted air early in life led to an accumulation of abdominal fat and insulin resistance in mice even if they ate a normal diet, according to new research.

3 Dec 2010

Spherix announces results of D-tagatose Phase 3 trial for Type 2 diabetes

Spherix Incorporated, an innovator in biotechnology for therapy in diabetes, metabolic syndrome and atherosclerosis; and providers of technical and regulatory consulting services to food, supplement, biotechnology and pharmaceutical companies, today announced results from its first Phase 3 trial post hoc analysis in which the higher body mass index (BMI) of the U.S. population relative to the Indian population was a likely key contributor to the more positive effects of D-tagatose in the lowering of HbA1c levels in the U.S. population. Initial results were announced on October 7.

2 Dec 2010

Medical, socioeconomic, and gender-based factors impact global women's health issues

Access to quality reproductive healthcare for women around the globe is a fundamental aspect of a woman's human rights, freedom, equity, and right to control her own body. A Special Section on Global Women's Reproductive Health in the current issue of Journal of Women's Health, a peer-reviewed publication published by Mary Ann Liebert, Inc., explores the compelling medical, socioeconomic, and gender-based factors that impact global women's health issues. The Special Focus articles are available free online.

1 Dec 2010

Research could lead to new drug treatment for metabolic diseases

A team of Harvard School of Public Health (HSPH) scientists report finding a molecular "switch" that can "turn off" some cellular processes that are protective against aging and metabolic diseases. While more research is needed, the findings may open doors for new drug treatments to halt or slow development of metabolic diseases like type 2 diabetes or heart disease. The research findings appear in the December 1, 2010 issue of Cell Metabolism.

1 Dec 2010

Metabolic Syndrome News and Research

Latest Metabolic Syndrome News and Research

Genetic expression can be modified with natural substances to prevent chronic illness

Breastfeeding can partially offset long-term side effects of cancer treatment

Scripps Research receives NIH grant to develop therapies for circadian rhythm disorders

First Round Table Meeting on Metabolomics & Diabetes takes place in Vienna

Shionogi brings KAPVAY ADHD drug to the U.S market

Esperion Therapeutics commences ETC-1002 Phase 2 clinical study for cardio-metabolic diseases

Liver transplant recipients develop PTMS, face high risk of cardiovascular disease

Diet low in micronutrients can contribute to metabolic syndrome

Florida Hospital, Sanford-Burnham and Takeda enter obesity research collaboration

Pregnant women veterans face increase risk of mental health problems

Isis commences ISIS-APOCIIIRx Phase 1 trial in hypertriglyceridemia

VIVUS seeks marketing approval of QNEXA in the EU

Study links large waistline to increased risk of heart problems and type 2 diabetes

VIVUS submits briefing document to FDA in effort to secure regulatory approval for QNEXA

Spherix Phase 2 diabetes clinical trial determines minimum D-tagatose dose capable of reducing HbA1c

Expert panel explores how to engage pediatricians, primary care physicians in preventing childhood obesity

Exposure to polluted air leads to accumulation of abdominal fat and insulin resistance

Spherix announces results of D-tagatose Phase 3 trial for Type 2 diabetes

Medical, socioeconomic, and gender-based factors impact global women's health issues

Research could lead to new drug treatment for metabolic diseases

Innovation in neuroscience drug discovery - eBook eBook

Leveraging the Radian ASAP in standard casework

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Metabolic Syndrome News and Research

Latest Metabolic Syndrome News and Research

Innovation in neuroscience drug discovery - eBook eBook

Leveraging the Radian ASAP in standard casework

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Newsletters you may be interested in